Compare IDEXX Laboratories, Inc. (IDXX) vs Oxford Lane Capital Corp (OXLC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Oxford Lane Capital Corp — how do they compare? IDEXX Laboratories, Inc. trades at $560 (market cap $44.48B), while Oxford Lane Capital Corp trades at $8.84 (market cap $866.15M). The key difference: IDEXX Laboratories, Inc. is far larger — about 51.4× Oxford Lane Capital Corp's market cap, and Oxford Lane Capital Corp pays a 27.06% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| IDXX | OXLC | |
|---|---|---|
Market Cap | $44.48B | $866.15M |
Sector | Health | Financials |
52-Week High | $766.68 | $19.90 |
52-Week Low | $520.87 | $8.15 |
Enterprise Value | $45.38B | — |
Dividend Yield | — | 27.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDXX trades at $563.79, down 0.64% today but maintains strong fundamental momentum with consistent earnings beats and robust profitability. The stock shows bullish technical signals with support at $563 and resistance at $572, while valuation metrics remain elevated. Recent Q1 2026 results exceeded expectations with EPS of $3.47 versus $3.41 estimates, supporting the company's leadership in veterinary diagnostics.
Outlook remains positive given strong analyst support (59% buy ratings) and innovation pipeline, though premium valuations and competitive pressures present risks. Revenue growth trajectory and expanding margins provide fundamental support for continued upside potential in the pet healthcare sector.
OXLC trades at $8.87, up 1.14% today, but faces a bearish technical outlook with negative moving averages and oscillators. The stock shows mixed fundamentals with a low P/B of 0.83 but alarming profitability metrics including a -39.16% ROE and three consecutive quarterly EPS misses. Recent news highlights concerns over its 24% dividend yield sustainability and a sharp net asset value decline reported in May 2026.
The outlook is cautious due to deteriorating earnings, high dividend risks, and negative cash flow from operations. While the P/B ratio suggests potential undervaluation, significant headwinds from poor ROE, volatile revenue, and bearish analyst sentiment outweigh opportunities. Investors should prioritize risk management amid ongoing financial instability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Oxford Lane Capital Corp
Oxford Lane Capital Corp. is a non-diversified, closed-end management investment company. Its primary investment objective is to achieve high current income, with a secondary objective of capital appreciation. The company primarily invests in equity and junior debt tranches of collateralized loan obligations (CLOs), which are pools of corporate loans. OXLC is known for its high-yield distribution policy and provides investors with leveraged exposure to the CLO market.
Read more on OXLC →
